Drug Database
Back to search

Belgium· BE-AMP-SAM058116-00

Bleomycine Hikma 15000 IU

A bleomycin product containing bleomycin sulfate, registered in Belgium by Hikma Farmacêutica. The same ATC class is registered in 15 of our 19 countries.

ATC L01DC01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedBleomycine Hikma 15000 IUATCL01DC01REGISTER NO.BE-AMP-SAM058116-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bleomycin sulfateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bleomycin is registered in 15 of 19 countries.

Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search bleomycin products by name

Bleomycin · ATC L01DC01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Bleomycin Sulfate
Manufacturer
Hikma Farmacêutica
Country
Belgium (BE)
ATC code
L01DC01
ATC class
Bleomycin
Defined daily dose
3 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0025825
  • be_apb
    0701979

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

212 interactions on record for bleomycin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bleomycin against other medicinesHow interaction checks work

Bleomycin · interactions on record

212 records

  • 33 severe
  • 105 moderate
  • 15 minor
  • 59 info

Most severe, free to view

  • CladribineL01BB04severe
  • Brentuximab vedotinL01FX05severe
  • Brentuximab vedotinL01XC12severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bleomycin in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bleomycin products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Germany · Bleomedac
  • Estonia · Bleomycin Medac
  • Finland · Bleomycin Baxter
  • France · Bleomycine Bellon
  • Italy · Bleoprim
  • Lithuania · Bleomycin Medac
  • Luxembourg · Bleomycine Hikma
  • Latvia · Bleomycin Medac
  • Poland · Bleomedac
  • Portugal · Bleocin
  • Slovakia · Bleomedac

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/56339276-20d0-4e79-9c86-395fd8933a2c
GET /v1/drugs/56339276-20d0-4e79-9c86-395fd8933a2c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Bleomycine Hikma 15000 IU",
  "name_fr": "Bleomycine Hikma 15000 IU",
  "name_nl": "Bleomycine Hikma 15000 IU",
  "amp_code": "SAM058116-00",
  "strengths": [
    "15.0000",
    "15.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Bleomycin Sulfate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Bleomycin",
  "authorisation_numbers": [
    "BE058116"
  ]
}
API referenceMCP serverPlans

See everything about bleomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console